Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subanesthetic esketamine for postoperative depression and anxiety in kidney transplantation
ChiCTR2100046136Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD) and anxiety disorder (3 arms), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoint: Hospital Anxiety and Depression Scale score. Started Jun 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on ChiCTR2100046136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046136.